Omontys (peginesatide)
Conditional
- Region
- 🇪🇺 EU
- Active substance
- peginesatide
- Company
- Takeda Global Research and Development Centre (Europe)
- Status
- Application withdrawn
- Therapeutic area
- Anemia
- Designations
- Conditional
- Application
- EMEA/H/C/002600
- ATC
- B03XA
- Official record
- www.ema.europa.eu
Indication
treatment of symptomatic anaemia associated with chronic kidney disease (CKD)
Regulatory milestones
No milestones recorded in the last year.
Follow Omontys
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.